Status
Conditions
Treatments
About
The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Previous treatment with MMF, CTX, tacrolimus, Cyclosporin A (CsA), large doses of immunoglobulin and methylprednisolone (MP), plasmapheresis or renal replacement therapy within the past 12 weeks. Oral glucocorticoids, azathioprine, intravenous MP (≤80mg/d), short-time CsA (<2 weeks) or leflunomide (<4 weeks) are allowed
ALT or AST increase twice above the upper limit of the normal range
Hyperglycemia is defined as fasting blood glucose level ≥7.0 mmol/L and/or postprandial blood sugar level>11.1 mmol/L
Known hypersensitivity or contraindication to any components of MMF, tacrolimus, CTX or glucocorticoids
History of present illness:
Other active diseases, such as:
Severe infection or need of antibiotic therapy
Female patients who are pregnant/breastfeeding or those patients (both gender) who refused contraception
Life-threatening complications such as large hydropericardium, pneumohemorrhagia, lupus encephalopathy and severe pulmonary hypertension or patients in need of MP pulse (>0.5g/d ) treatment because of aggravation of SLE
Known to be non-compliance or violation of the protocol base on investigator's judgement
Patient who participate of any other investigational drug study.
Primary purpose
Allocation
Interventional model
Masking
362 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal